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Abstract: The occurrence of a functional relationship between the release of metalloproteinases (MMPs) and the expression of 
cyclooxygenase (COX)-2, two inducible pro-inflammatory biomarkers with important pro-angiogenic effects, has recently been inferred. 
While brain endothelial cells play an essential role as structural and functional components of the blood-brain barrier (BBB), increased 
BBB breakdown is thought to be linked to neuroinflammation. Chemopreventive mechanisms targeting both MMPs and COX-2 however 
remain poorly investigated. In this study, we evaluated the pharmacological targeting of Sirt1 by the diet-derived and antiinflamma-
tory polyphenol resveratrol. Total RNA, cell lysates, and conditioned culture media from human brain microvascular endothelial cells 
(HBMEC) were analyzed using qRT-PCR, immunoblotting, and zymography respectively. Tissue scan microarray analysis of grade 
I–IV brain tumours cDNA revealed increased gene expression of Sirt-1 from grade I–III but surprisingly not in grade IV brain tumours. 
HBMEC were treated with a combination of resveratrol and phorbol 12-myristate 13-acetate (PMA), a carcinogen known to increase 
MMP-9 and COX-2 through NF-κB. We found that resveratrol efficiently reversed the PMA-induced MMP-9 secretion and COX-2 
expression. Gene silencing of Sirt1, a critical modulator of angiogenesis and putative target of resveratrol, did not lead to significant 
reversal of MMP-9 and COX-2 inhibition. Decreased resveratrol inhibitory potential of carcinogen-induced IκB phosphorylation in 
siSirt1-transfected HBMEC was however observed. Our results suggest that resveratrol may prevent BBB disruption during neuroin-
flammation by inhibiting MMP-9 and COX-2 and act as a pharmacological NF-κB signal transduction inhibitor independent of Sirt1.
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Introduction
Tumour-associated  angiogenesis,  a  fundamental 
process in tumour growth and metastasis, consists of 
recruiting EC toward an angiogenic stimulus.1 The 
cells  subsequently  proliferate  and  differentiate  to 
form endothelial tubes and capillary-like structures in 
order to deliver nutrients and oxygen to the tumour 
and  to  remove  the  products  of  its  metabolism.  In 
recent years, several pathways have, in addition to 
stimulation  of  tumor  angiogenesis,  been  suggested 
to  contribute  to  the  cell  metabolic  adaptations 
required  for  carcinogenesis,  which  include 
decreased  tumoural  apoptosis,  increased  invasion 
and  metastasis,  immune  suppression  and  tumour-
associated  inflammation.2,3  An  interesting  link 
between overexpression of pro-inflammatory markers 
such  as  matrix  metalloproteinase-9  (MMP-9)  and 
cyclooxygenase (COX)-2, and tumour angiogenesis 
was  recently  described  as  one  such  metabolic 
adaptative phenotype.4–6 While flavonoids and related 
polyphenolic compounds, such as resveratrol, have 
demonstrated  significant  antiinflammatory  activity, 
predominantly,  through  the  inhibition  of  NF-κB 
signaling,7  their  potential  therapeutic  application 
upon  the  cerebral  vascular  compartment  in 
neuroinflammation still remains poorly documented.
While  human  brain  microvascular  endothelial 
cells (HBMEC) play an essential role as structural 
and  functional  components  of  the  blood-brain 
barrier (BBB), its disruption by MMP-9 is believed 
to  favor  tumor  invasion.8,9  Recent  studies  in  fact 
delineated  a  unique  brain  endothelial  phenotype 
in  which  MMP-9  secretion  by  HBMEC  was 
increased upon treatment with the tumor-promoting 
agent  phorbol  12-myristate  13-acetate  (PMA).10,11 
Inhibition  of  MMP-9  secretion  was  demonstrated 
to reduce both in vitro invasion and angiogenesis in 
human  microvascular  EC.12  Among  the  signalling 
pathways  involved,  NF-κB  signalling  was  the  one 
that enabled the joint control of both MMP-9 and 
COX-2 inflammation marker expression.13,14
Recent  studies  point  to  Sirt1,  the  most  widely 
investigated and best known sirtuin, as a key regulator 
of  vascular  endothelial  homeostasis  controlling 
angiogenesis,  vascular  tone  and  endothelial 
dysfunction.15  Sirtuins  are  a  family  of  conserved 
proteins with deacetylase and ADP-ribosyltransferase 
activity encoded in humans by seven genes (Sirt1-7).16 
In  cancer  cells,  conflicting  reports  regarding  the 
expression of Sirt1 show either up-regulation17,18 or 
downregulation19 of Sirt1. Sirt1 may thus play a critical 
role in tumor progression, and drug resistance. While 
Sirt1  inhibitors  have  shown  promising  anticancer 
effects in animal models of cancer, its implication 
in  a  brain  EC  model  has  yet  to  be  documented. 
More  importantly,  the  expression  of  Sirt1  in  the 
brain  EC  compartment  as  well  as  impact  of  its 
pharmacological  targeting  is  still  unknown.  Given 
that  Sirt1-independent  mechanisms  were  recently 
reported  in  the  action  of  resveratrol,20  this  current 
study therefore focuses on resveratrol as a potential 
signal transduction inhibitor of carcinogen-mediated 
induction of the NF-κB pathway in a human brain EC 
model and questions the involvement of Sirt1.
Materials and Methods
reagents and cell culture
Bovine  serum  albumin  (BSA)  was  purchased  from 
MyClone  Laboratories  (Logan,  UT).  Electrophoresis 
reagents were purchased from Bio-Rad (Mississauga, 
ON). The enhanced chemiluminescence (ECL) reagents 
were  from  Perkin  Elmer  (Waltham,  MA).  Micro 
bicinchoninic acid protein assay reagents were from   
Pierce (Rockford, IL). The polyclonal antibodies against 
IκB and phospho-IκB were purchased from Cell Signaling 
(Danvers,  MA).  The  monoclonal  antibody  against 
GAPDH  was  from Advanced  Immunochemical  Inc. 
(Long Beach, CA). Horseradish peroxidase-conjugated 
donkey  anti-rabbit  and  anti-mouse  IgG  secondary 
antibodies  were  from  Jackson  ImmunoResearch 
Laboratories (West Grove, PA). Sodium dodecylsulfate 
(SDS) and all other reagents were from Sigma-Aldrich 
Canada. Human brain microvascular endothelial cells 
(HBMEC) were characterized and generously provided 
by Dr. Kwang Sik Kim of the Johns Hopkins University 
School of Medicine (Baltimore, MD).21,22 Cells were 
cultured  at  37  °C  under  a  humidified  atmosphere 
containing 5% CO2. All experiments were performed 
using passages 3 to 28.
gelatin zymography and immunoblotting 
procedures
Proteins from control and treated cells were separated by 
SDS-PAGE, and electrotransferred to polyvinylidene 
difluoride  membranes  as  previously  described.21 
Gelatin zymography was used to assess the extent of Sirt1 expression in inflammatory cerebral endothelium
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proMMP-9 activity as previously described.23 Briefly, 
an aliquot (20 µL) of the culture medium was sub-
jected to SDS-PAGE in a gel containing 0.1 mg/mL 
gelatin. The gels were then incubated in 2.5% Triton 
X-100 and rinsed in nanopure distilled H2O. Gels were 
further incubated at 37 °C for 20 hrs in 20 mM NaCl, 
5 mM CaCl2, 0.02% Brij-35, 50 mM Tris-HCl buffer, 
pH 7.6, then stained with 0.1% Coomassie Brilliant 
blue R-250 and destained in 10% acetic acid, 30% 
methanol in H2O. Gelatinolytic activity was detected 
as unstained bands on a blue background.
Total rnA isolation, cDnA synthesis  
and real-time quantitative rT-Pcr
Total RNA was extracted from cell monolayers using 
TriZol reagent (Life Technologies, Gaithersburg, MD). 
For cDNA synthesis, 2 µg of total RNA were reverse-
transcribed  using  a  high  capacity  cDNA  reverse 
transcription kit (Applied Biosystems, Foster City, CA). 
cDNA  was  stored  at  -80  °C  prior  to  PCR.  Gene 
expression was quantified by real-time quantitative PCR 
using iQ SYBR Green Supermix (Bio-Rad, Hercules, 
CA).  DNA  amplification  was  carried  out  using  an 
Icycler  iQ5  (Bio-Rad,  Hercules,  CA)  and  product 
detection  was  performed  by  measuring  binding  of 
the fluorescent dye SYBR Green I to double-stranded 
DNA.  The  QuantiTect  primer  sets  were  provided 
by Qiagen (Valencia, CA): MMP-9 (QT00040040), 
COX-2  (QT00040586),  β-Actin  (QT01136772). 
GAPDH  primer  sets  were  synthesized  by  Biocorp 
(Dollard-des-Ormeaux,  QC)  with  the  following 
sequences: forward CCATCACCATCTTCCAGGAG 
and  reverse  CCTGCTTCACCACCTTCTTG.  The 
relative  quantities  of  target  gene  mRNA  compared 
against two internal controls, GAPDH and β-Actin 
mRNA, were measured by following a ∆CT method 
employing an amplification plot (fluorescence signal 
vs. cycle number). The difference (∆CT) between the 
mean values in the triplicate samples of target gene and 
those of GAPDH and β-actin mRNAs were calculated 
by  iQ5  Optical  System  Software  version  2.0  (Bio-
Rad, Hercules, CA) and the relative quantified value 
(RQV) was expressed as 2-∆C
T.
TissueScan cDnA arrays of grade I-IV 
brain tumour tissues
TissueScan™ cancer and normal tissue cDNA arrays 
were  purchased  from  OriGene  (Rockville,  MD), 
covered 43 clinical samples of the brain cancer four 
stages  and  normal  tissues,  and  were  used  to  ana-
lyze differential Sirt1 gene expression according to 
the manufacturer’s recommendation. Tissue cDNAs 
of  each  array  are  synthesized  from  high  quality 
total RNAs of pathologist-verified tissues, normal-
ized  and  validated  with  β-actin  in  two  sequential 
qPCR analyses, and provided with clinical informa-
tion for 2 normal brain, 18 WHO grade I, 11 WHO 
grade II, 10 WHO grade III, and 2 WHO grade IV 
brain tumours.
Transfection method and rnA 
interference
Cells were transiently transfected with 20 nM siRNA 
(Qiagen)  against  Sirt1  (Hs_SIRT1_1  FlexiTube 
siRNA,  SI00098434)  or  scrambled  sequences 
(AllStar  Negative  Control  siRNA,  1027281)  using 
Lipofectamine 2000 (Invitrogen, ON). Specific gene 
knockdown was evaluated by qRT-PCR as described 
above. Small interfering RNA and mismatch siRNA 
were  synthesized  by  Qiagen  (Valencia,  CA)  and 
annealed to form duplexes.
Statistical data analysis
Data  statistical  significance  (P  values  ,0.05)  was 
assessed using Student’s unpaired t-test from three or 
more independent experiments.
Results
Sirt1 gene expression profiling  
in grade I-IV brain tumour tissues
Fourthy-eight  clinical  tissue  samples  were  first 
analyzed  for  Sirt1  gene  expression  profil  using 
TissueScan™  cancer  and  normal  tissue  cDNA 
arrays (OriGene, Rockville, MD) from 43 clinical 
samples  covering  brain  cancer  four  stages  and 
normal tissues as described in the methods section. 
We found that Sirt1 gene expression levels increased 
from  grade  I  to  grade  III  brain  tumour  tissues 
(Fig. 1, black bars), but not in grade IV as compared 
to normal brain tissue (Fig. 1, white bars). This 
suggests that discrepancy found in the literature 
regarding Sirt1 expression in tissue samples may 
be explained by the invasive stage status of a given 
tumour. Given that tumour samples are composed 
of  a  heterogeneous  cell  composition  including Annabi et al
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cancer,  inflammatory,  as  well  as  endothelial 
cells, we decided to focus our study on the Sirt1 
contribution  within  a  carcinogen-treated  brain-
associated endothelial cell compartment.
resveratrol dose-dependent inhibition  
of carcinogen-induced cOX-2 gene  
and protein expression
Various molecular mechanisms mediate inflammatory 
processes and angiogenesis, one of which is reflected 
by  increased  expression  of  the  inflammatory  bio-
marker COX-2.7 In order to investigate the effect of 
resveratrol on HBMEC-associated inflammation, we 
tested the effects of resveratrol on PMA-induced cell 
signaling in HBMEC by Western blotting. Cells were 
therefore treated with 1 µM of PMA in the presence 
of increasing concentrations of resveratrol for 18h 
and COX-2 expression was evaluated in cell lysates 
by Western Blotting (Fig. 2A). While 100 µM res-
veratrol was without effect on COX-2 basal expres-
sion, it significantly inhibited PMA-induced COX-2 
  protein expression (IC50 6.1 ± 2.2 µM, Fig. 2B) and 
gene (Fig. 2C) expression.
resveratrol inhibition of carcinogen-
induced MMP-9 gene expression  
and protein secretion
Among  the  secreted  enzymes  involved  in  ECM 
degradation,  matrix  metalloproteinases  (MMP)  are 
well-documented as being involved in EC migration 
and tubulogenesis.10,24 MMP-9, an enzyme involved in 
the degradation of the extracellular matrix (ECM), is 
secreted by a variety of cells and its presence was shown 
to be increased upon carcinogen promoting agents 
such as the phorbol ester PMA.25–27 HBMEC were 
first treated for 18 h with PMA. Gelatin zymography 
was then used to measure proMMP-9 levels, which 
were significantly increased upon PMA treatment in 
comparison to vehicle-treated cells (Fig. 3A). Addition 
of increasing concentrations of resveratrol to PMA-
treated cells resulted in a dose-dependent inhibition of 
MMP-9 activity (IC50 9.1 ± 0.8 µM, Fig. 3B and C). 
It was found that PMA also increased MMP-9 gene 
expression while the presence of resveratrol inhibited 
this increase suggesting transcriptional regulation of 
the MMP-9 gene (Fig. 3D).
carcinogen-induced IκB phosphorylation 
is inhibited by resveratrol
Among  MMP-9  expression  regulators,  the  nuclear 
factor-kappaB  (NF-κB)  signalling  pathway  has 
been  demonstrated  to  link  cancer  to  inflammatory 
diseases.28  We  therefore  assessed  whether  this 
signalling  was  activated  upon  PMA  treatment  and 
whether it was reflected in IkappaB (IκB) degradation. 
HBMEC were serum-starved then treated with 1 µM 
PMA for up to 30 minutes, lysates were isolated and 
IκB  phosphorylation  was  assessed  through  Western 
Blotting (Fig. 4A, upper panel). PMA signalling led 
to the phosphorylation of IκB peaking at 15 minutes.29 
Resveratrol effect on PMA-mediated phosphorylation 
of  IκB  was  next  assessed  in  order  to  demonstrate 
whether this mechanism contributes to the anti-COX-2 
inhibitory activities of resveratrol. Preincubation with 
30 µM resveratrol followed by a 30 min PMA treatment 
led to diminished IκB phosphorylation as demonstrated 
by the decreased ratios of phosphorylated IκB over 
GAPDH expression (Fig. 4B).
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Figure 1. Sirt1 gene expression profiling in grade I-IV brain tumour tissues. 
TissueScan™ cancer and normal tissue cDnA arrays from 43   clinical 
samples  covering  brain  cancer  four  stages  and  normal  brain  tissues 
were used to analyze differential Sirt1 gene expression. Tissue cDnAs 
of each array are synthesized from high quality total rnAs of pathologist-
verified tissues, normalized and validated with β-actin and provided with 
clinical information for 2 normal brain, 18 WhO grade I, 11 WhO grade II, 
10 WhO grade III, and 2 WhO grade IV brain tumours. 
Abbreviation: nB, normal brain tissue.Sirt1 expression in inflammatory cerebral endothelium
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Sirt1 contributes to the resveratrol 
inhibitory effect of PMA-induced IκB 
phosphorylation
Sirt1  is,  among  the  sirtuins  family,  documented 
to be targeted by resveratrol. In order to assess the 
contribution of Sirt1 in the resveratrol inhibition of 
NF-κB,  HBMEC  were  next  transiently  transfected 
with  a  scrambled  siRNA  sequence  (Mock)  or  an 
siRNA designed to downregulate Sirt1 (siSirt1) gene 
expression.  Preincubation  with  30  µM  resveratrol 
followed by a 30 min PMA treatment was performed 
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Figure 2. resveratrol dose-dependent inhibition of carcinogen-induced cOX-2 protein and gene expression. (A) hBMec were serum-starved in the 
  presence of various concentrations of resveratrol and in combination with vehicle or 1 µM PMA for 18 hours. Lysates were isolated, electrophoresed 
via SDS-PAGE, and immunodetection of COX-2 and GAPDH performed as described in the Methods section (NS, non specific immunoreactivity). 
(B) Scanning densitometry of cOX-2 expression was only performed in PMA-treated cells since no cOX-2 was detectable in vehicle-treated hBMec. 
Densitometric data of a representative blot is shown out of three independent experiments. (c) Total rnA isolation, rT-Pcr, and qPcr were performed 
as described in the Methods section to assess cOX-2 gene expression in the above-described conditions. (PMA = 1 µM; resveratrol = 30 µM).
notes: Data are representative of three independent qPCR experiments. Probability values of less than 0.05 were considered significant, and an asterisk 
(*) identifies such significance to the respective PMA treatment.Annabi et al
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in  Mock  and  in  siSirt1-transfected  cells.  Lysates 
were isolated, and GAPDH or IκB phosphorylation 
assessed through Western Blotting (Fig. 5A, upper 
panel). While ∼90% inhibition in Sirt1 gene expres-
sion  was  observed  in  siSirt1-transfected  cells 
(Fig. 5B), we found that resveratrol inhibitory poten-
tial was significantly diminished in those cells which 
had Sirt1 expression silenced (Fig. 5C, closed circles) 
in  comparison  to  Mock-transfected  cells  (Fig.  5C, 
open circles). PMA treatment by itself did not affect 
Sirt1 gene expression (not shown). This suggests that 
Sirt1 is indeed important in the inhibitory potential of 
resveratrol against PMA-mediated NF-κB signaling 
pathway.
Sirt1-independent inhibition by 
resveratrol of PMA-induced cOX-2 
expression and of PMA-induced 
MMP-9 secretion
Whether  Sirt1  serves  as  an  intermediate  in  the 
  resveratrol inhibitory potential was next   investigated 
on  PMA-treated  cells  for  COX-2  and  MMP-9 
expression.  As  described  above,  serum-starved 
mock and siSirt1-transfected HBMEC were treated 
with  PMA,  resveratrol  or  a  combination  of  both 
agents.  While  resveratrol  efficiently  inhibited 
both PMA-induced COX-2 (Fig. 6A) and MMP-9 
(Fig.  6B),  silencing  of  Sirt1  did  not  lead  to  any 
reversal  of  effect  as  resveratrol  still  efficiently 
inhibited  COX-2  and  MMP-9.  This  suggests  that 
resveratrol inhibition of PMA-induced COX-2 and 
MMP-9 is a Sirt1 independent event.
Discussion
The  adaptive  mechanisms  responsible  for  EC 
metabolic  adaptation  and  survival  under  pro-
carcinogenic  stimulation,  or  as  encountered  within 
a  tumour  microenvironment,  still  remain  poorly 
documented.  While  interest  has  been  manifested 
towards  cancer  therapies  that  jointly  target  EC 
angiogenic and inflammatory phenotypes, the design, 
synthesis and evaluation of flavonoid derivatives that 
target neurodegenerative disorders have accordingly 
paved  the  road  to  strategies  leading  to  decreased 
extracellular  matrix  (ECM)  degradation  and 
inflammation processes.30 The objectives of this current 
study were first to trigger in vitro pro-carcinogenic 
stimulation of a brain microvascular EC model using 
PMA  in  combination  with  resveratrol,  and  assess 
impact  on  inflammation  biomarkers  MMP-9  and 
COX-2 expression. Secondly, given that resveratrol is 
a well documented pharmacological agonist of Sirt1, 
PMA
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(c) Scanning densitometry was used to quantify the extent of proMMP-9 gelatinolytic activity in the combined PMA and resveratrol treatments. Data shown 
is representative of two independent experiments. (D) Total rnA isolation and qrT-Pcr were performed as described in the Methods section to assess 
MMP-9 gene expression in the above-described conditions. (PMA = 1 µM; resveratrol = 30 µM).
notes: Data are representative of three independent qPCR experiments. Probability values of less than 0.05 were considered significant, and an asterisk 
(*) identifies such significance to the respective PMA treatment.Sirt1 expression in inflammatory cerebral endothelium
Drug Target Insights 2012:6  7
but that conflicting data regarding Sirt1 expression in 
glioblastoma has been reported,17–19 we specifically 
explored its contribution to the resveratrol anti-PMA 
pharmacological properties.
Our first objective was confirmed by the increases 
in  inflammatory  biomarkers  MMP-9  and  COX-2 
expression  upon  carcinogenic  stimulation  in 
HBMEC. As such, the calculated IC50 concentrations 
of resveratrol inhibitory effects extracted from our 
in  vitro  model  closely  approximate  those  actual 
concentrations  assessed  in  the  plasma  ranging 
between 1.2–2.6 µM.31,32 Both biomarkers expression 
was  inhibited  by  resveratrol  and  this  required 
inhibition  of  the  NF-κB  signaling  pathway  as 
validated by reduced IκB phosphorylation. Inhibition 
of NF-κB (p65 subunit) translocation to the nucleus 
by resveratrol is a mechanism that has already been 
inferred  in  an  experimental  hepatocarcinogenesis 
model.33 Our data thus indirectly support this nuclear 
translocation  effect  since  IκB  phosphorylation, 
which ultimately releases p65 and p50 in order to 
allow nuclear translocation, was found inhibited by 
resveratrol in our model (Fig. 4B). Although not the 
scope of this study, ChIP assays  may further help 
address NF-κB capacity to bind COX-2 and MMP-9 
promoter regions.
Given that the involvement of Sirt1still remains 
undefined, at least within the carcinogenic context 
we report herein, our second objective was evaluated 
and  confirmed  a  Sirt1-independent,  but  efficient, 
targeting by resveratrol of the PMA-induced NF-κB 
signaling pathway that ultimately leads to reduced 
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MMP-9 and COX-2 expression. Our current data do 
not support Sirt1 requirements in our brain EC model 
suggesting that cell specificity may dictate resveratrol 
efficacy in inhibiting MMP-9 in neuroinflammation 
or brain tumor angiogenesis. In accordance with our 
current study, the presence or absence of Sirt1, as 
assessed through the use of Sirt1-null animals, had 
no effect on incidence and tumor load induced by 
a two-stage carcinogenesis protocol.42 In fact, only 
part of the chemopreventive effect of resveratrol was 
attributed to Sirt1.34 Moreover, while most biological 
effects of sirtuins have so far been attributed to their 
enzymatic activity, opposing effects of sirtuins on 
neuronal survival have also been reported suggestive 
of  Sirt1-mediated  neuroprotection  independent  of 
deacetylase activity.35 Although resveratrol is a potent 
pharmacological  agonist  of  Sirt1,36  and  expected 
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sirnA sequence (Mock) or a sirnA designed to downregulate Sirt1 (siSirt1) as described in the Methods section. (A) Mock and siSirt1-transfected 
hBMec were then serum-starved for 30 minutes in the presence or not of 50 µM resveratrol, then treated with 1 µM PMA for the indicated time. Lysates 
were isolated, electrophoresed via SDS-PAge and immunodetection of phosphorylated IκB (P-IκB) and gAPDh proteins was performed as described in 
the Methods section. (B) Total rnA isolation, rT-Pcr, and qPcr were performed as described in the Methods section to assess Sirt1 gene expression in 
the Mock and siSirt1-transfected hBMec. (c) Quantification was performed by scanning densitometry of the autoradiograms obtained in (A). 
notes: Data were expressed as the percent of basal phospho-IκB/gAPDh ratios in vehicle (open circles) and resveratrol pre-treated cells (closed circles). 
Densitometric data of a representative blot out of three is shown.
to induce deacetylation of known Sirt1 substrates 
such  as  NF-κB,  PGC-1α,  and  p53,37,38  one  may 
now  have  to  consider  alternate  mechanisms  of 
resveratrol to those mediated through Sirt1. Among 
those  mechanisms,  several  flavonoids  have  been 
reported to interfere with the inducible nitric-oxide 
synthase activity, as well as of both the COX and 
5-lipoxygenase  pathways.39,40  Interestingly,  Sirt1 
is  a  putative  suppressive  regulator  found  in  the 
MMP-9 gene promoter,41 and activation of Sirt1 by 
resveratrol was found to be required for inhibition of 
PMA-induced MMP-9 expression.42,43
Generalized  interpretation,  in  part  due  to  the 
occurrence of multiple in vitro cell culture models, 
has put forward large number of mechanisms of action 
attributed  to  flavonoids  commonly  found  in  fruits, 
vegetables, wine, or tea as their metabolites also can act Sirt1 expression in inflammatory cerebral endothelium
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as potent antioxidants and free radical scavengers.21,44 
Whether the inhibitory effects observed in vitro are 
due  to  resveratrol  metabolites  has  therefore  to  be 
promptly considered and carefully addressed. As such, 
oral bioavailability of resveratrol has been reported to 
be low because it is rapidly metabolized in intestines 
and liver into conjugated forms such as glucuronate 
and sulfonate.45 In mammals, less than 5% of the oral 
dose is being observed as free resveratrol in blood 
plasma.45–47 The most abundant resveratrol metabolites 
being  trans-resveratrol-3-O-glucuronide  and  trans-
resveratrol-3-sulfate,48  the  impact  of  glucuronides 
and of these sulfate conjugates will also ultimately 
need further study.
In  summary,  the  present  study  has  confirmed 
resveratrol as a signal transduction inhibitor against 
carcinogen-mediated  induction  of  COX-2  and 
MMP-9. Moreover, evidence that the NF-κB pathway 
may  be  inhibited  through  the  targeting  of  IκK 
phosphorylation capacity that ultimately may reduce 
both the acquisition of a pro-inflammatory phenotype, 
as  reflected  by  decreased  COX-2  expression,  and 
the  acquisition  of  pro-angiogenic  phenotype,  as 
reflected by a decrease in MMP-9. Our results further 
discriminate the role of Sirt1 in the anti-PMA action 
of  resveratrol  suggesting  alternative  intracellular 
targeting.  Whether  other  sirtuin  members  are 
involved remains to be investigated. BBB disruption 
during neuroinflammation may, in light of our results, 
be  pharmacologically  reduced  by  a  specific  class 
of  flavonoids  acting  as  NF-κB  signal  transduction 
inhibitors.
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